SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is trending following a strong earnings beat and robust Q1 guidance driven by surging data center demand, sparking intense community debate despite the impressive financials. While many anticipate a significant rally, others caution of a 'sell the news' scenario, citing ongoing skepticism regarding AI valuation and perceived market manipulation impacting options traders.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

The Trade Desk (TTD) is experiencing a significant sell-off after providing softer-than-expected Q1 guidance, despite beating Q4 revenue and earnings estimates, fueling intense investor debate. Many express frustration over the prolonged stock decline and executive compensation, while others view the sharp drop as an oversold opportunity, highlighting the company's profitability and strong customer retention in the competitive ad tech sector.

Larimar Therapeutics, Inc. Is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics mitochondrial disorders and Friedreich's ataxia. The company was founded in 2005 and is headquartered in Bala Cynwyd, PA.

Larimar Therapeutics Inc

Larimar Therapeutics is trending after receiving FDA Breakthrough Therapy Designation for its Friedreich's ataxia treatment, igniting bullish comparisons to multi-billion dollar acquisitions, though a recently priced $100 million public offering is fueling debate among investors over dilution versus strategic funding for commercialization.

Infinite Money Glitch ($IMG) is revolutionizing DeFi on Solana by leveraging the Token2022 program's advanced tax extension capabilities to create a truly innovative reward system for token holders.  At its core, $IMG implements a seamless 5% tax on all transactions - whether buying, selling, or transferring tokens. This tax is automatically collected and distributed to holders in SOL, creating a sustainable passive income stream for the community. 4.5% of the tax gets sent to holders, while .5% gets sent to an Infrastructure wallet to help with development, marketing and general infrastructure.  What sets $IMG apart is its implementation of Solana's Token2022 program, enabling automated and efficient reward distribution without relying on external smart contracts.

Infinite Money Glitch

Infinite Money Glitch (IMG CRYPTO) is trending as its community celebrates a one-year anniversary and the recent launch of its "incinerator," which executes continuous buybacks and burns to tighten supply. Holders are bullish on its passive income mechanism, which automatically distributes Solana rewards.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

An increase in ImmunityBio's (IBRX) shares outstanding, stemming from debt conversion and founder Patrick Soon-Shiong's reaffirmed majority ownership, is driving fervent community debate over the stock's true free float and massive short interest; this occurs amidst recent global regulatory approvals and significant revenue growth, leaving bulls anticipating a short squeeze while skeptics raise dilution concerns.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals (AUPH) is actively discussed ahead of its Q4 earnings report, with investor sentiment focused on overdue updates for the AUR200 Phase 2 pipeline and continued Lupkynis sales performance. Community hopes for a significant catalyst, potentially a buyout, are tempered by past management communication issues, despite notable institutional accumulation.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas Semiconductor is trending due to its recent earnings report, emphasizing its critical role in advanced GaN and SiC power solutions for next-gen AI data centers and EVs, especially within NVIDIA's ecosystem. The community is keenly watching for concrete, revenue-generating partnerships that could validate its long-term potential, despite current revenue declines prompting market debate.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

NVAX is highly discussed ahead of its upcoming earnings call, with the community focused on potential strategic partnerships for its Matrix-M adjuvant in oncology and C. difficile, alongside intense speculation about a short squeeze given high institutional ownership and significant short interest. Investors are also actively debating management's effectiveness in capitalizing on the company's valuable pipeline amidst a changing vaccine landscape.

Direxion Shares ETF Trust - Direxion Daily South Korea Bull 3X Shares

Direxion Daily South Korea Bull 3X Shares

KORU is skyrocketing on an extraordinary rally in South Korean equities, propelled by semiconductor powerhouses Samsung and SK Hynix amid booming High Bandwidth Memory chip demand for AI processing. The community is actively discussing its immense gains, anticipating further momentum from the country's recent short-selling ban and ongoing market reforms.

Circle Internet Group, Inc. is a financial technology company that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. The company was founded by Jeremy J. Allaire and Patrick Sean Neville in August 2013 and is headquartered in New York, NY.

Circle Internet Group Inc. - Ordinary Shares - Class A

Circle

Circle (CRCL) is rallying significantly after a strong Q4 earnings report highlighted robust growth in USDC circulation and adjusted EBITDA, propelling community discussion about its role as a foundational stablecoin platform. Bulls anticipate a substantial short squeeze and triple-digit price targets, while a vocal contingent of bears warns of an overextended rally ripe for profit-taking amidst ongoing debates about its valuation and crypto market correlation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The patient had a tumor shrinkage of 50% and notable decline in the tumor biomarker CA-125, the company said.&nbsp;</li><li>The patient experienced only low-grade treatment-emergent adverse effects and continued treatment.</li><li>The company is now eyeing confirmation of the partial response observed in both its patients in subsequent imaging assessments.</li></ul>Shares of Aprea Therapeutics, Inc. (APRE) rallied 15% on Wednesday after the company said that it observed tumor shrinkage in a patient enrolled in an early-stage trial of its experimental drug APR-1051.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.aprea.com/news-releases/news-release-details/aprea-therapeutics-announces-additional-positive-clinical">reported</a> a second unconfirmed partial response in a patient with advanced endometrial cancer being treated at the 220 mg dose level. The patient had a tumor shrinkage of 50% and notable decline in the tumor biomarker CA-125, the company said.The patient experienced only low-grade treatment-emergent adverse effects and continued treatment, Aprea said. The first patient to achieve a partial response at 150 mg dose levels also remains on therapy as the experimental oral therapy is generally well-tolerated, the company added.<h2 class="st-heading-2">Steps Ahead</h2>The company is now eyeing confirmation of the partial response observed in both its patients in subsequent imaging assessments. Further updates from the trial are expected in the second quarter of 2026. The study is aimed at evaluating the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of APR-1051 in patients with advanced solid tumors and nearly 22 patients have been treated at varying doses of 10mg to 220 mg.“We believe the magnitude of tumor reduction and the substantial drop in CA-125 in this patient provides further evidence of APR-1051’s biologic activity and potential therapeutic impact,” said Eugene Kennedy, Chief Medical Advisor at Aprea.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around APRE stock increased from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume improved from ‘extremely low’ to ‘normal’ levels.According to data from Koyfin, all the three analysts covering the stock rate it ‘Buy’ or higher. The 12-month average price target on the stock is at $5.33, representing a potential upside of about 788% from last day’s closing price.<a href="https://stocktwits.com/symbol/APRE">APRE stock</a> has declined 80% over the past 12 months.&nbsp;Read More: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://SPRB Stock Drops After Company Pushes Back Application Submission Timeline For Experimental Sanfilippo Syndrome Therapy">SPRB Stock Drops After Company Pushes Back Application Submission Timeline For Experimental Sanfilippo Syndrome Therapy</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Aprea Therapeutics logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Aprea Therapeutics Stock Rises After Company Reports Second Unconfirmed Case Of Tumor Reduction In Trial

The company reported a second unconfirmed partial response in a patient with advanced endometrial cancer being treated at the 220 mg dose level.

Equity

The company reported a second unconfirmed partial response in a patient with advanced endometrial cancer being treated at the 220 mg dose level.


Aprea Therapeutics Advanced Cancer Trial Shows Promising Results, Stock Soars

Aprea Therapeutics shares rise after promising Phase 1 trial results with APR-1051 in cancer treatment.read more...

New Strong Sell Stocks for January 19th

APRE, NFE and CZR have been added to the Zacks Rank #5 (Strong Sell) List on January 19, 2026.

 New Strong Sell Stocks for Jan. 14

APRE, CULP and PSKY have been added to the Zacks Rank #5 (Strong Sell) List on Jan.13, 2026.

Marc Duey Acquires 21,459 Shares of Aprea Therapeutics (NASDAQ:APRE) Stock

Aprea Therapeutics, Inc. (NASDAQ:APRE - Get Free Report) Director Marc Duey purchased 21,459 shares of the firm's stock in a transaction on Wednesday, December 10th. The shares were acquired at an...

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of cancer therapeutics. It is involved in the development and commercialization of novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company was founded by Vladimir Bykov, Klas Gota Wiman, Staffan Stromblad, Natalia Issaeva, Galina Selivanova, and Wen Jie Bao in 2002 and is headquartered in Doylestown, PA.

APRE
Aprea Therapeutics Inc

Feed

News

Sentiment

Fundamentals

Info

Latest APRE News

APREAprea Therapeutics Inc